Literature DB >> 28655809

Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?

Simone Ferrero1, Martin Dreyling2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28655809      PMCID： PMC5566011          DOI： 10.3324/haematol.2017.167627

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

Review 1.  Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.

Authors:  Simone Ferrero; Daniela Drandi; Barbara Mantoan; Paola Ghione; Paola Omedè; Marco Ladetto
Journal:  Hematol Oncol       Date:  2011-04-02       Impact factor: 5.271

2.  Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

Authors:  Daniela Drandi; Lenka Kubiczkova-Besse; Simone Ferrero; Nadia Dani; Roberto Passera; Barbara Mantoan; Manuela Gambella; Luigia Monitillo; Elona Saraci; Paola Ghione; Elisa Genuardi; Daniela Barbero; Paola Omedè; Davide Barberio; Roman Hajek; Umberto Vitolo; Antonio Palumbo; Sergio Cortelazzo; Mario Boccadoro; Giorgio Inghirami; Marco Ladetto
Journal:  J Mol Diagn       Date:  2015-08-28       Impact factor: 5.568

3.  Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

Authors:  Christiane Pott; Carsten Schrader; Stefan Gesk; Lana Harder; Markus Tiemann; Thorsten Raff; Monika Brüggemann; Matthias Ritgen; Benedikt Gahn; Michael Unterhalt; Martin Dreyling; Wolfgang Hiddemann; Reiner Siebert; Peter Dreger; Michael Kneba
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

4.  Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

Authors:  Alexandra Albertsson-Lindblad; Arne Kolstad; Anna Laurell; Riikka Räty; Kirsten Grønbæk; Jan Sundberg; Lone Bredo Pedersen; Elisabeth Ralfkiær; Marja-Liisa Karjalainen-Lindsberg; Christer Sundström; Mats Ehinger; Christian Geisler; Mats Jerkeman
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

5.  Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing.

Authors:  Dörte Wren; Brian A Walker; Monika Brüggemann; Mark A Catherwood; Christiane Pott; Kostas Stamatopoulos; Anton W Langerak; David Gonzalez
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

6.  A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.

Authors:  Philippe Armand; Robert Redd; Jad Bsat; Sangeetha Mayuram; Angela Giardino; David C Fisher; Ann S LaCasce; Caron Jacobson; Matthew S Davids; Jennifer R Brown; Li Weng; Jennifer Wilkins; Malek Faham; Arnold S Freedman; Robin Joyce; Eric D Jacobsen
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

7.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

8.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

Authors:  V H J van der Velden; G Cazzaniga; A Schrauder; J Hancock; P Bader; E R Panzer-Grumayer; T Flohr; R Sutton; H Cave; H O Madsen; J M Cayuela; J Trka; C Eckert; L Foroni; U Zur Stadt; K Beldjord; T Raff; C E van der Schoot; J J M van Dongen
Journal:  Leukemia       Date:  2007-02-08       Impact factor: 11.528

9.  Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

Authors:  M Ladetto; M Brüggemann; L Monitillo; S Ferrero; F Pepin; D Drandi; D Barbero; A Palumbo; R Passera; M Boccadoro; M Ritgen; N Gökbuget; J Zheng; V Carlton; H Trautmann; M Faham; C Pott
Journal:  Leukemia       Date:  2013-12-17       Impact factor: 11.528

10.  Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.

Authors:  Simone Ferrero; Luigia Monitillo; Barbara Mantoan; Daniela Barbero; Elisa Genuardi; Sara Barbiero; Elisa Bernocco; Daniele Caracciolo; Marco Ruella; Daniela Drandi; Manuela Zanni; Federica Renna; Chiara Lobetti Bodoni; Angela Gueli; Roberto Passera; Pellegrino Musto; Mario Boccadoro; Corrado Tarella; Marco Ladetto
Journal:  Ann Hematol       Date:  2013-06-05       Impact factor: 3.673
View more
  5 in total

Review 1.  Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.

Authors:  Michael J Buege; Anita Kumar; Brianne N Dixon; Laura A Tang; Terry Pak; Jennifer Orozco; Tim J Peterson; Kathryn T Maples
Journal:  Ann Pharmacother       Date:  2020-02-20       Impact factor: 3.154

Review 2.  Mantle Cell Lymphoma: Which Patients Should We Transplant?

Authors:  James N Gerson; Stefan K Barta
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

3.  The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of Mantle Cell Lymphoma in the Bone Marrow.

Authors:  Ifeyinwa E Obiorah; Hao-Wei Wang; David Ma; Eddie Martin; Wyndham H Wilson; Raul Braylan
Journal:  Am J Clin Pathol       Date:  2022-05-04       Impact factor: 5.400

4.  Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing.

Authors:  Lea Amalia Lind Elkjær; Oriane Cédile; Marcus Høy Hansen; Christian Nielsen; Michael Boe Møller; Niels Abildgaard; Jacob Haaber; Charlotte Guldborg Nyvold
Journal:  Leuk Res Rep       Date:  2022-08-09

Review 5.  Advances in the assessment of minimal residual disease in mantle cell lymphoma.

Authors:  Dayoung Jung; Preetesh Jain; Yixin Yao; Michael Wang
Journal:  J Hematol Oncol       Date:  2020-09-24       Impact factor: 17.388
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.